Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Protara Therapeutics, Inc. (TARA)

Protara Therapeutics Q1 net loss widens to $17.8 million; cash $177.4 million

Negative Impact 3 of 5 earnings Written later

Protara Therapeutics reported a first-quarter 2026 net loss of $17.8 million, or $0.31 per share, up from $11.9 million, or $0.29 per share, a year earlier. The filing reports no revenue, and the loss widened as research and development and general and administrative expenses rose, but the company said its $177.4 million in cash and marketable securities should fund operations into 2028.

Key points

  • Net loss of $17.8 million, or $0.31 per share, for the quarter ended March 31, 2026, versus $11.9 million, or $0.29 per share, a year earlier
  • Research and development expenses rose to $13.6 million from $9.1 million, mainly due to ADVANCED-2 trial costs and ADVANCED-3 start-up costs
  • Cash, cash equivalents and marketable debt securities totaled $177.4 million as of March 31, 2026, expected to support operations into 2028
  • The company intends to submit a Biologics License Application for TARA-002 in lymphatic malformations in the second half of 2027

The filing

CompanyProtara Therapeutics, Inc. (TARA)
Form8-K, current report
Filed with the SECMay 13, 2026, 8:05 AM ET
Accession number0001213900-26-055462

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.